Overview

Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilar UDENYCA^® (pegfilgrastim-cbqv). Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.

05/07/20	Coherus BioSciences Reports First Quarter 2020 Financial Results – First Quarter UDENYCA® Net Sales of $116.2 Million – –Net Income of $35.6 Million – – Non-GAAP Net Income of $49.8 Million – REDWOOD CITY, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and reported
05/04/20	Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference REDWOOD CITY, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will make a virtual presentation at BofA Securities 2020 Health Care Conference on Thursday, May 14, 2020 at 1:00 p.m. ET .
04/22/20	Coherus BioSciences to Report First Quarter Financial Results on May 7th REDWOOD CITY, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will be released after market close on Thursday, May 7, 2020 . Starting at 4:30 p.m.
04/15/20	Coherus BioSciences Prices $200.0 Million Convertible Senior Subordinated Notes Offering REDWOOD CITY, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced the pricing of its offering of $200,000,000 aggregate principal amount of 1.500% convertible senior subordinated notes due 2026 (the “notes”) in a private

View All